Treatment With Gemcitabine and TRA-8 Anti-Death Receptor-5 mAb Reduces Pancreatic Adenocarcinoma Cell Viability In Vitro and Growth In Vivo

Journal of Gastrointestinal Surgery

Volumn 10, Issue 9, 2006, Pages 1291-1300

  DeRosier, Leo Christopher ^a   Huang, Zhi Qiang ^a   Sellers, Jeffrey C ^a   Buchsbaum, Donald J ^a   Vickers, Selwyn M ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

gemcitabine; monoclonal antibody; Pancreatic cancer; TRAIL death receptor antibody

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CASPASE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; LIPOCORTIN 5; MONOCLONAL ANTIBODY; TNFRSF10B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL; APOPTOSIS; ARTICLE; DRUG POTENTIATION; DRUG SCREENING; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; NUDE MOUSE; PANCREAS CARCINOMA; PANCREAS TUMOR; TUMOR CELL LINE;

ANIMALS; ANNEXIN A5; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CASPASES; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; HUMANS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33751012407     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gassur.2006.08.007     Document Type: Article

References (41)

1. Burris III H.A., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15 (1997) 2403-2413
2. Berlin J.D., et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20 (2002) 3270-3275
3. Di Costanzo F., et al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: A randomised phase II trial of the Italian oncology group for clinical research (GOIRC). Br J Cancer 93 (2005) 185-189
4. Louvet C., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23 (2005) 3509-3516
5. Rocha Lima C.M., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22 (2004) 3776-3783
6. Stathopoulos G.P., et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 12 (2001) 101-103
7. Stathopoulos G.P., et al. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: A multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 14 (2003) 388-394
8. Stathopoulos G.P., et al. Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: An intergroup, multicenter, phase II study. Ann Oncol 15 (2004) 224-229
9. Kindler H.L., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23 (2005) 8033-8040
10. MJ Moore, D Goldstein, Hamm J, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Proceedings of the 2005 Gastrointestinal Cancers Symposium. Miami: January 27-29, 2005. American Society of Clinical Oncology, Alexandria VA.
11. Pitti R.M., et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271 (1996) 12687-12690
12. Wiley S.R., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
13. Almasan A., and Ashkenazi A. Apo2L/TRAIL: Apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14 (2003) 337-348
14. Bonavida B., et al. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics. [review]. Int J Oncol 15 (1999) 793-802
15. Guo Y., et al. A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Chem 280 (2005) 41940-41952
16. MacFarlane M., et al. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 272 (1997) 25417-25420
17. Marsters S.A., et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 7 (1997) 1003-1006
18. Pan G., et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277 (1997) 815-818
19. Sheridan J.P., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818-821
20. Pan G., et al. The receptor for the cytotoxic ligand TRAIL. Science 276 (1997) 111-113
21. Rudner J., et al. Type I and type II reactions in TRAIL-induced apoptosis-Results from dose-response studies. Oncogene 24 (2005) 130-140
22. Emery J.G., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273 (1998) 14363-14367
23. Jo M., et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6 (2000) 564-567
24. Lawrence D., et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7 (2001) 383-385
25. Ichikawa K., et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7 (2001) 954-960
26. Pukac L., et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92 (2005) 1430-1441
27. Burdick M.D., et al. Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell lines. J Biol Chem 272 (1997) 24198-24202
28. Crouch S.P., et al. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods 160 (1993) 81-88
29. Petty R.D., et al. Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolumin Chemilumin 10 (1995) 29-34
30. Cossarizza A., et al. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5, 5′, 6,6′-tetrachloro-1, 1′, 3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem Biophys Res Commun 197 (1993) 40-45
31. Smiley S.T., et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci U S A 88 (1991) 3671-3675
32. Ibrahim S.M., et al. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 23 (2001) 72-79
33. Mori T., et al. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Surgery 138 (2005) 71-77
34. Ozawa F., et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett 163 (2001) 71-81
35. Rowinsky E.K. Targeted induction of apoptosis in cancer management: The emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 23 (2005) 9394-9407
36. Straughn Jr. J.M., et al. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol 101 (2006) 46-54
37. Xu Z.W., et al. Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Res 23 (2003) 251-258
38. Kaliberov S.A., et al. Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity. Cancer Gene Ther 13 (2006) 203-214
39. Stennicke H.R., et al. Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem 273 (1998) 27084-27090
40. Hylander B.L., et al. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 3 (2005) 22
41. Jacob D., et al. Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther 12 (2005) 109-115